Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €37.36 EUR
Change Today +0.413 / 1.12%
Volume 0.0
3M4 On Other Exchanges
As of 9:34 AM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

masimo corp (3M4) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/23/15 - €38.43
52 Week Low
09/24/14 - €15.94
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MASIMO CORP (3M4)

masimo corp (3M4) Related Businessweek News

No Related Businessweek News Found

masimo corp (3M4) Details

Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. It offers Masimo Signal Extraction Technology (SET) with measure-through-motion and low-perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. The company also provides Masimo rainbow SET Platform, which includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor multiple blood-based measurements, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from pleth; noninvasively monitor hemoglobin, carboxyhemoglobin, and methemoglobin; monitor arterial oxygen saturation; and calculates oxygen content and oxygen reserve index. In addition, it offers SedLine brain function monitoring technology that measures the brain’s electrical activity by detecting EEG signals; capnography and gas monitoring products, such as external plug-in-and-measure capnography and gas analyzers, integrated modules, and handheld capnograph and capnometer devices; O3 regional oximetry for tissue oxygen saturation measurement; SafetyNet, a patient surveillance, remote monitoring, and clinician notification solution; and Halo Index, an indicator that facilitates trending and assessment of physiological measurements. Further, the company offers remote alarm/monitoring solutions, software, and connectivity solutions. The company’s patient monitoring technologies incorporate a monitor or circuit board and sensors, including proprietary single-patient use, reusable and rainbow ReSposable sensors, and patient cables. Masimo Corporation provides its products directly, as well as through distributors and original equipment manufacturers partners to hospitals, emergency medical service providers, physician offices, veterinarians, long term care facilities, and consumers. The company was founded in 1989 and is headquartered in Irvine, California.

1,200 Employees
Last Reported Date: 02/17/15
Founded in 1989

masimo corp (3M4) Top Compensated Officers

Founder, Chairman and Chief Executive Officer
Total Annual Compensation: $830.8K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $346.1K
Chief Operating Officer
Total Annual Compensation: $307.8K
President of Worldwide Oem Business & Blood M...
Total Annual Compensation: $347.4K
President of Worldwide Sales, Professional Se...
Total Annual Compensation: $332.4K
Compensation as of Fiscal Year 2014.

masimo corp (3M4) Key Developments

Masimo Corporation Provides Earnings Guidance for the Second Quarter of 2015

Masimo Corporation provided earnings guidance for the second quarter of 2015. For the quarter, the company expects that its product revenue will range from $147.0 million to $148.0 million, and that its royalty revenue for the quarter will be approximately $8.0 million. As a result, the company now expects its total second quarter revenues to range from $155.0 million to $156.0 million. The company also estimates that its second quarter of 2015 fully-diluted GAAP earnings per share will be between $0.35 and $0.36.

Turgut Ozal Medical Centre Liver Hospital Installs Masimo’s Noninvasive, Continuous Haemoglobin (SpHb®) Technology to Monitor Surgical Patients

Masimo announced that Turgut Ozal Medical Centre Liver Hospital in Malatya, Turkey, has installed Masimo’s noninvasive, continuous haemoglobin (SpHb®) technology to monitor surgical patients. SpHb is a breakthrough measurement that noninvasively and continuously measures total haemoglobin in the blood, and offers real-time visibility to changes – or lack of changes – in haemoglobin between invasive blood sampling. Laboratory haemoglobin values are only available intermittently and are often delayed. Clinicians can estimate blood loss, but this can both overstate and understate actual blood loss. SpHb monitoring may provide additional insight between invasive blood sampling when: The SpHb trend is stable and the clinician may otherwise think haemoglobin is dropping; The SpHb trend is rising and the clinician may otherwise think haemoglobin is not rising fast enough; The SpHb trend is dropping and the clinician may otherwise think haemoglobin is stable.

Masimo Receives CE Mark and Full Market Release of MightySat™ Rx Fingertip Pulse Oximeter for Clinical Use in CE Countries

Masimo announced the CE Mark and full market release of MightySat™ Rx fingertip pulse oximeter for clinical use in CE countries, offering the same Masimo SET® Measure-Through Motion and Low Perfusion™ pulse oximetry technology used in hospitals. MightySat™ Rx fingertip pulse oximeter provides oxygen saturation (SpO2), pulse rate (PR), Perfusion Index (PI), and Pleth Variability Index (PVI®). Bluetooth®-enabled versions of MightySat Rx allow clinicians to track and trend up to 12 hours of patient measurements on smart mobile devices, and to share that data via standard CSV files as well as transfer to Apple’s Health app. MightySat Rx enables accurate noninvasive spot-checking of oxygen saturation (SpO2) and pulse rate (PR) for adult and paediatric patients even during motion and low perfusion. MightySat Rx measures and displays Perfusion Index (PI), which reflects the strength of the pulsatile signal. MightySat can also measure and display Pleth Variability Index (PVI®), a measure of the dynamic changes in the perfusion index that occur during one or more complete respiratory cycle/s. MightySat Rx is available in three versions for patients who weigh more than 30 kg (66 lbs): MightySat Rx " Measures and displays SpO2, PR, and PI. MightySat Rx, Bluetooth " Adds Bluetooth LE radio for transfer of parameter data to Apple iOS® and select Android™ mobile devices. MightySat Rx, Bluetooth and PVI. Standard features include: Measure-Through Motion and Low Perfusion performance. Signal I.Q.® to assess measurement confidence. Rugged, lightweight design for operation in challenging environments. Long battery life 'up to 15 hours with two standard AAA alkaline batteries. Comfortable design with silicon finger pad to mold to patients’ fingers.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
3M4:GR €37.36 EUR +0.413

3M4 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CONMED Corp $56.72 USD -0.13
ICU Medical Inc $99.92 USD +0.58
Integra LifeSciences Holdings Corp $64.13 USD +0.13
Merit Medical Systems Inc $25.56 USD +0.39
NuVasive Inc $55.01 USD +0.08
View Industry Companies

Industry Analysis


Industry Average

Valuation 3M4 Industry Range
Price/Earnings 32.3x
Price/Sales 3.7x
Price/Book 6.8x
Price/Cash Flow 30.9x
TEV/Sales 3.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MASIMO CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at